Gilead Sciences
What matters nowUpdated 9 h ago
- The most recent approval is Bixlenvo, a once-daily single-tablet HIV regimen of bictegravir and lenacapavir, cleared by the FDA on August 27, 2026 for adults who are virologically suppressed; the release gives no launch date or price 1.
- GILD trades at $148.80 on the pooled 24/7 venue price, down 1.23% from the $150.65 previous close. Sharp moves came on August 18 (+3.82%), September 8 (-2.88%) and October 9 (+3.27%).
- Q2 2026 revenue rose 10% to $7.8 billion, led by HIV medicines, Trodelvy and Livdelzi; the GAAP loss of $8.45 per diluted share reflected about $9.08 per share of acquired in-process R&D tied to the Arcellx, Tubulis and Ouro Medicines deals, and cash fell to $3.2 billion from $10.6 billion at the end of 2025 2.
- Over the twelve months to June 30, 2026, revenue was $30.5 billion and free cash flow $12.9 billion, a 7.0% free cash flow yield at a $184.7 billion market cap. In the last 180 days insiders filed 18 planned sales worth $25.7 million and no purchases.
- Gilead reports third-quarter 2026 results on an estimated October 29, 2026, not yet confirmed. The FDA action date for anito-cel is December 23, 2026, and the FDA action date for once-weekly oral Yeztugo is February 2, 2027 3.
Gilead Sciences newsroom · Aug 27
SEC Form 8-K, Exhibit 99.1 (Gilead) · Aug 4
EATG (reprint of Gilead press release) · Jun 15
Gilead Sciences is a biopharmaceutical company based in Foster City, California. Its revenue rests on HIV medicines, which were about 70 percent of 2025 sales, led by Biktarvy, plus liver disease, oncology and cell therapy products. Its newer launches are Yeztugo, a twice-yearly HIV prevention injection, and Trodelvy, which won FDA approval in June 2026 as a first-line treatment for triple-negative breast cancer. In 2026 Gilead bought Arcellx, whose anito-cel myeloma cell therapy has an FDA action date of December 23, 2026, and Tubulis, a drug-conjugate developer, and Ouro Medicines.
How it makes money
Gilead sells branded medicines to hospitals, specialty pharmacies, wholesalers and governments, mainly in the United States, which produced about 71 percent of 2025 total revenue. Revenue depends on patient volume, net price and new launches in a few large franchises: Biktarvy alone was $14.3 billion, about half of 2025 product sales. Royalty and contract revenue is small but lumpy, and it jumped in 2025 on one-time intellectual property sales. Acquisitions drive the reported profit line in 2026: acquired R&D charges for Arcellx, Tubulis and Ouro pushed the second quarter of 2026 to a GAAP loss of $8.45 per diluted share, while non-GAAP results were also a loss.
Last 12 monthsChart & venues →
Valuation & fundamentalsFull financials →
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price. Quarterly statements →
Biggest businessesAll products & projects →
Biktarvy
Largest product: $3.77 billion of sales in Q2 2026, up 7% year over year.
Descovy
Q2 2026 sales rose 48% to $967 million.
Yeztugo (lenacapavir)
Q2 2026 sales of $232 million, up from $15 million a year earlier. Once-weekly oral filing has an FDA date of February 2, 2027.
Next: FDA target action date for once-weekly oral Yeztugo · 2027-02-02
Trodelvy (sacituzumab govitecan)
Q2 2026 sales rose 26% to $457 million. First-line triple-negative breast cancer approval came in June 2026.
Latest newsAll news →
CEO Daniel O'Day sells 15,000 Gilead shares at about $147.90 on October 1
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on October 1, 2026, in two blocks: 12,000 shares at about $147.72 and 3,000 at about $148.63.
Gilead widens royalty-free lenacapavir licences to cover once-yearly HIV prevention
Gilead expanded six existing royalty-free voluntary licences for lenacapavir to cover the investigational once-yearly injection for HIV prevention, across 120 high-incidence countries, mostly low- and lower-middle-income.
CEO Daniel O'Day sells 15,000 Gilead shares at about $148.64
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on September 1, 2026, in three blocks priced from $146.94 to $149.94, a weighted average of about $148.64.
FDA approves Bixlenvo, Gilead's once-daily bictegravir and lenacapavir HIV pill
The FDA approved Bixlenvo (bictegravir 75 mg and lenacapavir 50 mg), a once-daily single-tablet HIV regimen for adults who are virologically suppressed and can replace their current regimen.
Gilead Q2 2026 revenue rises 10% to $7.8 billion; GAAP loss on acquired R&D charges
Gilead reported second-quarter 2026 total revenue of $7,803 million, up 10% from a year earlier, led by HIV medicines, Trodelvy and Livdelzi.
CEO Daniel O'Day sells 15,000 Gilead shares under a 10b5-1 plan
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on August 3, 2026, in three open-market blocks priced from about $129.17 to $131.47, a weighted average of about $130.31.
Products & businesses
Biktarvy
Largest product: $3.77 billion of sales in Q2 2026, up 7% year over year.
Descovy
Q2 2026 sales rose 48% to $967 million.
Yeztugo (lenacapavir)
Q2 2026 sales of $232 million, up from $15 million a year earlier. Once-weekly oral filing has an FDA date of February 2, 2027.
Next: FDA target action date for once-weekly oral Yeztugo · 2027-02-02
Trodelvy (sacituzumab govitecan)
Q2 2026 sales rose 26% to $457 million. First-line triple-negative breast cancer approval came in June 2026.
Cell Therapy (Yescarta and Tecartus)
Q2 2026 cell therapy sales fell 14% to $417 million.
Livdelzi (seladelpar)
Q2 2026 sales more than doubled to $167 million.
What it's building next
Anito-cel (anitocabtagene autoleucel)
BLA accepted by the FDA; action date December 23, 2026. Gilead completed the Arcellx acquisition on April 28, 2026.
Next: FDA action date (PDUFA) for anito-cel · 2026-12-23
Once-weekly islatravir and lenacapavir (HIV treatment)
Phase 3 ISLEND-1 and ISLEND-2 met the Week 48 endpoint. Global filings are planned; no FDA date is set.
Tubulis antibody-drug conjugate platform
Acquired in 2026 for a $3.15 billion upfront payment; Q2 2026 included a $3.1 billion acquired R&D charge.
Segments
| Segment | Revenue | Share | |
|---|---|---|---|
| HIV Biktarvy, Descovy, Genvoya, Odefsey, Yeztugo, Sunlenca and other HIV medicines. The largest business by far. | $20.75B | 70.5% | |
| Liver Disease Vemlidy, Livdelzi, Epclusa (sofosbuvir/velpatasvir), Viread and Hepcludex for hepatitis B, hepatitis D, hepatitis C and primary biliary cholangitis. | $3.22B | 10.9% | |
| Oncology Trodelvy plus the cell therapy business, which includes Yescarta and Tecartus. Total of the two reported lines. | $3.24B | 11.0% | |
| Veklury Remdesivir, the COVID-19 antiviral. Sales are falling as COVID-19 treatment demand declines. | $911.0M | 3.1% | |
| Other products and royalties Remaining product sales and royalty, contract and other revenue, which rose to $527 million in 2025 from $144 million in 2024. | $1.33B | 4.5% |
Fiscal 2025 · from the annual report
Valuation & fundamentals
TTM through 2026-06-30 from SEC filings (some quarters derived from annual and year-to-date figures). Ratios use our pooled 24/7 price.
Financial statements
| Metric | TTM | Q2 FY2026 2026-06-30 | Q1 FY2026 2026-03-31 | Q4 FY2025 2025-12-31 | Q3 FY2025 2025-09-30 | Q2 FY2025 2025-06-30 | Q1 FY2025 2025-03-31 | Q4 FY2024 2024-12-31 | Q3 FY2024 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.46B | $7.80B +10% | $6.96B +4% | $7.92Bd +5% | $7.77B +3% | $7.08B +2% | $6.67B -0% | $7.57Bd +6% | $7.54B +7% |
| Gross profit | $24.24B | $6.22Bd +12% | $5.51Bd +8% | $6.30Bd +5% | $6.20Bd +4% | $5.58Bd +3% | $5.13Bd -0% | $5.99Bd +19% | $5.97Bd +9% |
| Operating income | −$2.50B | −$10.39B -520% | $2.59B +16% | $1.98Bd -19% | $3.33B +275% | $2.47B -6% | $2.24B | $2.45Bd +52% | $888.0M -66% |
| Net income | −$3.24B | −$10.50B -636% | $2.02B +54% | $2.18Bd +22% | $3.05B +144% | $1.96B +21% | $1.31B | $1.78Bd +25% | $1.25B -43% |
| EPS (diluted) | $-2.67 | $-8.45 -642% | $1.61 +55% | $1.74d +23% | $2.43 +143% | $1.56 +21% | $1.04 | $1.42d +26% | $1.00 -42% |
| Operating cash flow | $13.55B | $3.57Bd +332% | $2.54B +45% | $3.33Bd +12% | $4.11Bd -5% | $827.0Md -38% | $1.76B -21% | $2.98Bd +37% | $4.31Bd +146% |
| Capital expenditure | $609.0M | $140.0Md +31% | $117.0M +13% | $205.0Md +39% | $147.0Md +4% | $107.0Md -18% | $104.0M -1% | $147.0Md -32% | $141.0Md +16% |
| Share buybacks | $1.44B | $355.0Md -33% | $419.0M -43% | $230.0Md -34% | $435.0Md +45% | $527.0Md +427% | $730.0M +83% | $350.0Md +133% | $300.0Md +0% |
| Cash & equivalents | — | — | — | — | — | — | — | — | — |
| Total debt | $26.25B | $26.25B | $22.17B | $24.94B | $24.94B | $24.95B | $24.95B | $26.71B | $23.25B |
| Shares outstanding | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | 1.24B | 1.25B | 1.25B | 1.25B |
| Metric | FY2025 2025-12-31 | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 |
|---|---|---|---|---|
| Revenue | $29.44B +2% | $28.75B +6% | $27.12B -1% | $27.28B |
| Cost of revenue | $6.23B -0% | $6.25B -4% | $6.50B +15% | $5.66B |
| Gross profit | $23.21Bd +3% | $22.50Bd +9% | $20.62Bd -5% | $21.62Bd |
| Operating income | $10.02B +503% | $1.66B -78% | $7.61B +4% | $7.33B |
| EBIT | $10.02B +503% | $1.66B -78% | $7.61B +4% | $7.33B |
| Depreciation & amortization | $370.0M -3% | $381.0M +8% | $354.0M +10% | $323.0M |
| Interest expense | $1.02B +5% | $977.0M +3% | $944.0M +1% | $935.0M |
| Income tax | $1.29B +509% | $211.0M -83% | $1.25B -0% | $1.25B |
| Net income | $8.51B +1673% | $480.0M -92% | $5.67B +23% | $4.59B |
| EPS (diluted) | $6.78 +1684% | $0.38 -92% | $4.50 +24% | $3.64 |
| Dividends per share | $3.16 +3% | $3.08 +3% | $3.00 +3% | $2.92 |
| Diluted shares (weighted) | 1.25B | 1.25B | 1.26B | 1.26B |
| Operating cash flow | $10.02B -7% | $10.83B +35% | $8.01B -12% | $9.07B |
| Capital expenditure | $563.0M +8% | $523.0M -11% | $585.0M -20% | $728.0M |
| Share buybacks | $1.92B +67% | $1.15B +15% | $1.00B -28% | $1.40B |
| Dividends paid | $4.00B +2% | $3.92B +3% | $3.81B +3% | $3.71B |
| Cash & equivalents | — | — | — | $5.41B |
| Long-term debt (incl. current portion) | $24.94B | $26.71B | $24.99B | $25.23B |
| Total debt | $24.94B | $26.71B | $24.99B | $25.23B |
| Total assets | $59.02B | $58.99B | $62.13B | $63.17B |
| Total liabilities | $36.32Bd | $39.66Bd | $39.29Bd | $41.93Bd |
| Shareholders' equity | $22.70B | $19.33B | $22.83B | $21.24B |
| Shares outstanding | 1.24B | 1.25B | 1.25B | 1.25B |
From XBRL data in SEC filings. Small figures under each value: change vs the same period a year earlier. d = derived (e.g. Q4 = full year − first nine months).
NewsFull archive →
CEO Daniel O'Day sells 15,000 Gilead shares at about $147.90 on October 1
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on October 1, 2026, in two blocks: 12,000 shares at about $147.72 and 3,000 at about $148.63.
Gilead widens royalty-free lenacapavir licences to cover once-yearly HIV prevention
Gilead expanded six existing royalty-free voluntary licences for lenacapavir to cover the investigational once-yearly injection for HIV prevention, across 120 high-incidence countries, mostly low- and lower-middle-income.
CEO Daniel O'Day sells 15,000 Gilead shares at about $148.64
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on September 1, 2026, in three blocks priced from $146.94 to $149.94, a weighted average of about $148.64.
FDA approves Bixlenvo, Gilead's once-daily bictegravir and lenacapavir HIV pill
The FDA approved Bixlenvo (bictegravir 75 mg and lenacapavir 50 mg), a once-daily single-tablet HIV regimen for adults who are virologically suppressed and can replace their current regimen.
Gilead Q2 2026 revenue rises 10% to $7.8 billion; GAAP loss on acquired R&D charges
Gilead reported second-quarter 2026 total revenue of $7,803 million, up 10% from a year earlier, led by HIV medicines, Trodelvy and Livdelzi.
CEO Daniel O'Day sells 15,000 Gilead shares under a 10b5-1 plan
Chairman and CEO Daniel O'Day sold 15,000 Gilead shares on August 3, 2026, in three open-market blocks priced from about $129.17 to $131.47, a weighted average of about $130.31.
EU regulator backs Trodelvy plus Keytruda for first-line PD-L1-positive breast cancer
The EMA's CHMP recommended Trodelvy combined with Keytruda for adults with unresectable or metastatic triple-negative breast cancer who have not had prior systemic therapy for metastatic disease and whose tumors are PD-L1 positive (CPS 10 or higher).
Gilead and Merck report Week 48 data for once-weekly oral HIV pill islatravir/lenacapavir
Gilead and Merck reported Week 48 Phase 3 results for once-weekly islatravir and lenacapavir, meeting the primary endpoint in both ISLEND trials.
FDA approves Trodelvy for first-line metastatic triple-negative breast cancer
The FDA approved Trodelvy as a first-line treatment for metastatic triple-negative breast cancer.
FDA accepts application for once-weekly oral Yeztugo, PDUFA date February 2, 2027
The FDA accepted Gilead's supplemental application for a once-weekly oral 300 mg lenacapavir tablet for HIV prevention, with a PDUFA action date of February 2, 2027.
Gilead and Merck report positive Phase 3 ISLEND-1 and ISLEND-2 results for once-weekly HIV pill
Gilead and Merck said both Phase 3 ISLEND trials of once-weekly oral islatravir plus lenacapavir met their Week 48 primary endpoint.
Merck and Gilead stop Phase 3 KEYNOTE-D46/EVOKE-03 lung cancer study
Merck and Gilead said an independent Data Monitoring Committee recommended stopping the Phase 3 trial of Trodelvy plus Keytruda in previously untreated PD-L1-high non-small cell lung cancer.
Livdelzi Phase 3 IDEAL trial meets primary endpoint in PBC patients with elevated ALP
Gilead said the Phase 3 IDEAL trial of Livdelzi (seladelpar) met its primary endpoint, a composite of alkaline phosphatase at or below 1.0 times the upper limit of normal with a 15% or greater drop from baseline at Week 52.
FDA grants accelerated approval to Hepcludex, first US treatment for chronic hepatitis delta
The FDA granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus infection who have no cirrhosis or compensated cirrhosis.
EMA's CHMP backs Trodelvy monotherapy for first-line triple-negative breast cancer in Europe
The EMA's CHMP adopted a positive opinion recommending Trodelvy as a monotherapy for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitors.
Gilead Q1 2026 beats: product sales ex-Veklury up 8%, product guidance raised, EPS guidance cut to a loss
Gilead's first-quarter revenue rose 4% to $6.96 billion, and product sales excluding Veklury grew 8% to $6.8 billion.
FDA grants priority review to Gilead's once-daily bictegravir plus lenacapavir HIV pill
The FDA accepted Gilead's new drug application for a once-daily single tablet of bictegravir 75 mg and lenacapavir 50 mg and granted priority review.
Gilead completes Arcellx acquisition ahead of anito-cel launch
Gilead completed its acquisition of Arcellx on April 28, 2026, so it now owns anito-cel outright.
Gilead to buy Germany's Tubulis for $3.15 billion upfront, up to $5 billion total
Gilead agreed to buy Munich-based Tubulis, a developer of antibody-drug conjugates, for $3.15 billion in cash at closing plus up to $1.85 billion in milestones.
Gilead to acquire Ouro Medicines for $1.675 billion upfront, autoimmune T-cell engager
Gilead agreed to acquire privately held Ouro Medicines, which is developing T-cell engagers for autoimmune diseases.
Gilead agrees to buy Arcellx for $115 per share in cash plus CVR, about $7.8 billion
Gilead agreed to acquire the rest of Arcellx, the partner on anito-cel, a BCMA-directed CAR T-cell therapy for multiple myeloma.
Gilead reports 2025 results and guides 2026 product sales to $29.6-30.0 billion
Gilead reported fourth-quarter and full-year 2025 results and set 2026 guidance.
Gilead raises quarterly dividend 3.8% to $0.82 per share
Gilead announced a 3.8% increase in its quarterly cash dividend to $0.82 per share, starting with the first quarter of 2026.
Gilead Sciences reports fiscal Q3 2025 results: revenue $7.77B, up 3% from a year earlier
Gilead Sciences filed a Form 8-K with the SEC on Oct 30, 2025, 4:04 PM ET, reporting an event dated Oct 30, 2025.
SEC filings
| Oct 2, 26 | 4 | Form 4: O'Day Daniel Patrick (Chairman & CEO, Director) — open-market sale 15,000 sh | sec.gov ↗ |
| Sep 23, 26 | 4 | Form 4: Burkhart Erin (SVP, Controllership) — option exercise 2,223 sh, tax withholding 768 sh | sec.gov ↗ |
| Sep 16, 26 | 4 | Form 4: Dickinson Andrew D (Chief Financial Officer) — open-market sale 3,000 sh | sec.gov ↗ |
| Sep 16, 26 | 4 | Form 4: Mercier Johanna (Chief Comm & Corp Aff Officer) — open-market sale 3,000 sh | sec.gov ↗ |
| Sep 15, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 15, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Sep 11, 26 | 4 | Form 4: Dickinson Andrew D (Chief Financial Officer) — option exercise 2,797 sh, tax withholding 1,347 sh | sec.gov ↗ |
| Sep 11, 26 | 4 | Form 4: Berger Dietmar (Chief Medical Officer) — option exercise 533 sh, tax withholding 263 sh | sec.gov ↗ |
| Sep 11, 26 | 4 | Form 4: Mercier Johanna (Chief Comm & Corp Aff Officer) — option exercise 2,797 sh, tax withholding 1,347 sh | sec.gov ↗ |
| Sep 11, 26 | 4 | Form 4: Cain Wettan Keeley M (EVP Gen Counsel, Legal & Comp) — option exercise 590 sh, tax withholding 285 sh | sec.gov ↗ |
| Sep 11, 26 | 4 | Form 4: O'Day Daniel Patrick (Chairman & CEO, Director) — option exercise 8,780 sh, tax withholding 4,230 sh | sec.gov ↗ |
| Sep 2, 26 | 4 | Form 4: O'Day Daniel Patrick (Chairman & CEO, Director) — open-market sale 15,000 sh | sec.gov ↗ |
| Aug 27, 26 | 4 | Form 4: WELTERS ANTHONY (Director) — option exercise 18,000 sh, open-market sale 18,000 sh | sec.gov ↗ |
| Aug 26, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 26, 26 | N-PX | N-PX: Proxy voting record | sec.gov ↗ |
| Aug 21, 26 | 4 | Form 4: Bluestone Jeffrey (Director) — option exercise 5,000 sh, open-market sale 5,000 sh | sec.gov ↗ |
| Aug 20, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: Dickinson Andrew D (Chief Financial Officer) — open-market sale 3,000 sh | sec.gov ↗ |
| Aug 18, 26 | 4 | Form 4: Mercier Johanna (Chief Comm & Corp Aff Officer) — option exercise 25,000 sh, open-market sale 28,000 sh | sec.gov ↗ |
| Aug 17, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 17, 26 | 144 | Form 144: Notice of proposed insider sale | sec.gov ↗ |
| Aug 11, 26 | 4 | Form 4: Cain Wettan Keeley M (EVP Gen Counsel, Legal & Comp) — option exercise 6,002 sh, tax withholding 2,908 sh | sec.gov ↗ |
| Aug 7, 26 | SCHEDULE 13D/A | SCHEDULE 13D/A: Activist/controlling ownership report (5%+) (amended) | sec.gov ↗ |
| Aug 6, 26 | S-3ASR | S-3ASR: Automatic shelf registration statement | sec.gov ↗ |
| Aug 6, 26 | 10-Q | 10-Q: Quarterly report for the period ended Jun 30, 2026 | sec.gov ↗ |
Insider trades, 12 months
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-01 | O'Day Daniel Patrick Chairman & CEO, Director | Sale 10b5-1 plan | 15.0K | $147.90 | $2.2M |
| 2026-09-15 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 plan | 3.0K | $144.22 | $432.6K |
| 2026-09-15 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 plan | 3.0K | $145.29 | $435.9K |
| 2026-09-01 | O'Day Daniel Patrick Chairman & CEO, Director | Sale 10b5-1 plan | 15.0K | $148.64 | $2.2M |
| 2026-08-26 | WELTERS ANTHONY Director | Sale 10b5-1 plan | 18.0K | $148.62 | $2.7M |
| 2026-08-20 | Bluestone Jeffrey Director | Sale 10b5-1 plan | 5.0K | $145.02 | $725.1K |
| 2026-08-17 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 plan | 28.0K | $137.64 | $3.9M |
| 2026-08-17 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 plan | 3.0K | $138.36 | $415.1K |
| 2026-08-03 | O'Day Daniel Patrick Chairman & CEO, Director | Sale 10b5-1 plan | 15.0K | $130.31 | $2.0M |
| 2026-07-15 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 plan | 3.0K | $129.92 | $389.8K |
| 2026-07-15 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 plan | 3.0K | $129.93 | $389.8K |
| 2026-07-01 | O'Day Daniel Patrick Chairman & CEO, Director | Sale 10b5-1 plan | 15.0K | $126.29 | $1.9M |
| 2026-06-15 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 plan | 3.0K | $125.40 | $376.2K |
| 2026-06-15 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 plan | 3.0K | $123.92 | $371.8K |
| 2026-06-01 | O'Day Daniel Patrick Chairman & CEO, Director | Sale 10b5-1 plan | 15.0K | $131.46 | $2.0M |
| 2026-05-15 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 plan | 28.0K | $131.29 | $3.7M |
| 2026-05-15 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 plan | 3.0K | $132.27 | $396.8K |
| 2026-04-28 | O'Day Daniel Patrick Chairman & CEO, Director | Sale 10b5-1 plan | 10.0K | $129.16 | $1.3M |
| 2026-04-15 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 plan | 3.0K | $140.96 | $422.9K |
| 2026-04-15 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 plan | 3.0K | $140.96 | $422.9K |
| 2026-03-27 | O'Day Daniel Patrick Chairman & CEO, Director | Sale 10b5-1 plan | 10.0K | $136.82 | $1.4M |
| 2026-03-16 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 plan | 3.0K | $144.23 | $432.7K |
| 2026-03-16 | Mercier Johanna Chief Comm & Corp Aff Officer | Sale 10b5-1 plan | 3.0K | $144.23 | $432.7K |
| 2026-02-27 | O'Day Daniel Patrick Chairman & CEO, Director | Sale 10b5-1 plan | 10.0K | $144.79 | $1.4M |
| 2026-02-17 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 plan | 3.0K | $154.43 | $463.3K |